肿瘤细胞可利用抑制性免疫检查点蛋白程序性死亡蛋白1 (programmed death-1,PD-1)及程序性死亡蛋白配体1(programmed death ligand-1,PD-L1)逃脱T细胞介导的细胞毒作用,阻断PD-1/PD-L1通路的治疗性抗体对越来越多的实体瘤产生持续的临床效应.此文综述PD-1/PD-L1信号通路阻断剂在激活宿主抗经典霍奇金淋巴瘤免疫应答中的作用,并总结当前使用该治疗手段的临床研究.%Tumor cells can escape T-cell-mediated cellular cytotoxicity by exploiting inhibitory immune checkpoint proteins programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1).Indeed,therapeutic antibodies that block the PD-1/PD-L1 axis induce durable clinical responses against a growing list of solid tumors.This review focuses on the role of PD-1/PD-L1 blockade in unleashing host anti-tumor immune responses against classical Hodgkin lymphoma,and summarizes clinical studies of this approach performed to date.
展开▼
